



Welcome to this month's eNews



Is Investor Love for the Sector Returning This February?

The second month of the year always brings with it the aftermath of JPM Week, where the global life science investment community gathers to assess the hopes, dreams, and worries of the year ahead. There seemed to be a positive buzz emanating from a sunny San Francisco mixed with a sense of having been here before each year since 2021.

Tony Jones, CEO
One Nucleus

Captured in my article for [Business Weekly](#) recently, calling on the data presented at Genesis 2024, were some of the data giving cause for optimism that 2025 could be a turning point for the sector. This sense of recovery was added to by last week's BIA report '[UK biotech financing 2024](#)', indicating an almost doubling of equity finance being raised compared to the previous year. So, with innovation continuing to thrive, corporate product development pipelines needing to be bolstered, and investment beginning to flow, 2025 may just turn out to be a very good year.

Real treats for me personally this month have been the opportunity to review the keynote programme delivered at Genesis in December and collating the [One Nucleus Annual Awards](#) entries to send to the judges. Watch out for the shortlist announcement on 14 February. The One Nucleus Highlights publication detailed below will include the Genesis 2024 Review, over 11,000 words detailing the wisdom, best practice, and insights shared by the >40 speakers on the day, available in one good read. The Review could be considered a go-to resource on financing trends, engaging investors, dealing with valuation, positioning convergent technologies, and more from the day. Check out how you can place your profile within the publication your partners, colleagues, and potential customers will be reading.

In this month's issue, you will see further articles of insight from our members, including EY, Aon, and RSM UK, sharing on topics ranging from dealmaking trends to pay transparency regulations and the increasing impact of AI on the sector. Further, there is a case study from Alicia Gailliez reporting the 2024 collaboration with Domainex, a great example demonstrating how members can collaborate with One Nucleus to engage their target audience.

Staying in the Loop

Remain informed of all One Nucleus updates, disseminate your company's news, or track the announcements from other members, and make full use of our [website](#), [LinkedIn](#), or [X](#) pages. The [news stream](#) contains numerous updates from our community. Enjoy the read!

Tony Jones, CEO, One Nucleus



EY Firepower Report: Life Sciences Dealmaking – Trends In 2025

Life sciences dealmaking volume is stable, but value is down. The 2025 edition of the EY Firepower report explores how life sciences companies can secure a more confident future with smarter, smaller deals. [Find out more.](#)

UK Life Sciences: Funding, Collaboration and AI Adoption Will Be Key to Success in 2025

RSM UK's co-leads of life sciences, Laragh Jeanroy and Graham Bond, highlight three key themes dominating the sector in 2025. [Read more here.](#)


Life Sciences: a Structured Approach to Implementing Pay Transparency Practices

At our Genesis 2024 fringe event on 5 December, Aon's Suzanne Courtney, Human Capital Industry Leader, Life Sciences, EMEA, together with Matt Robinson, Life Science Industry Leader and Keaton Hoffman, Partner, Life Sciences, EMEA, discussed the impact of the EU's upcoming Pay Transparency Directive and the lessons we can learn from it. [Find out more.](#)

Life Sciences: The Impact of the CSRD Legislation on Executive Incentives

What impact will new EU legislation have on pay transparency and ESG reporting? At Aon's fringe event at Genesis 2024 in December, speakers explored the evolving role of environmental, social and governance (ESG) in executive incentives with the implementation of the Corporate Sustainability Reporting Directive (CSRD). [Read more here.](#)

Sponsor the One Nucleus Highlights Publication for More Visibility



5 Reasons to Sponsor the One Nucleus Highlights magazine:

- 1** It launches at **BIO-Europe Spring, the largest biopartnering conference in Europe** (attended by **3,700** potential partners) and taken to all our events
- 2** Hosted on the **One Nucleus website**, where **15k** visitors a month start their search for Partners
- 3** Highlighted in our monthly newsletter and at national and industry **conferences** attended by One Nucleus
- 4** Align your company with a feature about the **Genesis London Conference**
- 5** Your ad includes a **link** to your company's directory listing on our website, for extra visibility.

An [A4 page](#) starts at just £500+VAT. To be included please email info@onenucleus.com. Join us in showcasing recent One Nucleus Highlights and recognise the success you have helped create.

Horizon Europe Funding Survey

Innovate UK is keen to understand your organisation's appetite for applying to and participating in Horizon Europe calls in the future, and any barriers to entry into the programme. Take the survey [here](#).

How One Nucleus Helped Deliver a Successful Webinar Series for Domainex

Connecting with business partners, fellow innovators and key advisers is a vital part of the ecosystem's objectives to exchange knowledge and onward contact for mutual success. [Find out how](#) Domainex and One Nucleus worked together to deliver a series of drug discovery webinars to over 200 delegates.

Apply for our Boston Bootcamp

Deadline 14 February 2025

Find out more [here](#)






One Nucleus Events

Training Courses

Industry News

Corporate Patron

AstraZeneca 

Corporate Sponsors

CHESTERFORD
RESEARCH PARK

 **MSD**

AON

ThermoFisher
SCIENTIFIC

TaylorWessing

Copyright © 2025

One Nucleus is an international membership organisation for life science and healthcare companies.